{"id":"NCT02036515","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","officialTitle":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-12","primaryCompletion":"2016-06-06","completion":"2016-06-06","firstPosted":"2014-01-15","resultsPosted":"2017-07-24","lastUpdate":"2018-09-13"},"enrollment":464,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Ertugliflozin 5 mg","otherNames":["MK-8835","PF-04971729"]},{"type":"DRUG","name":"Ertugliflozin 15 mg","otherNames":["MK-8835","PF-04971729"]},{"type":"DRUG","name":"Placebo for ertugliflozin 5 mg","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":["Glucophage","Glucophage XR"]},{"type":"DRUG","name":"Sitagliptin","otherNames":["JANUVIAÂ®"]},{"type":"DRUG","name":"Glimepiride","otherNames":["AMARYL"]},{"type":"BIOLOGICAL","name":"Insulin","otherNames":[]},{"type":"DRUG","name":"Placebo for ertugliflozin 10 mg","otherNames":[]}],"arms":[{"label":"Ertugliflozin 5 mg","type":"EXPERIMENTAL"},{"label":"Ertugliflozin 15 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin. The primary objective of the trial is to assess the hemoglobin A1C (A1C)-lowering efficacy of the addition of ertugliflozin compared to the addition of placebo with an underlying hypothesis that addition of treatment with ertugliflozin provides greater reduction in A1C compared with the addition of placebo; the primary objective will be tested for both 5-mg and 15-mg doses of ertugliflozin.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1C at Week 26","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Ertugliflozin 5 mg","deltaMin":-0.78,"sd":null},{"arm":"Ertugliflozin 15 mg","deltaMin":-0.86,"sd":null},{"arm":"Placebo","deltaMin":-0.09,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":22},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28921862","32700393","32648108","32372382","32324082","32324065","31797522","31064361"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":156},"commonTop":["Hypoglycaemia","Nasopharyngitis","Back pain","Urinary tract infection"]}}